AstraZeneca Slips as Investors Look Ahead to October Results
The shares fell more than major US indexes, while Zacks consensus estimates point to lower quarterly earnings and higher revenue.
AstraZeneca shares fell 1.17% in the latest session, closing at $164.21. The decline was steeper than losses in the S&P 500, Dow and Nasdaq.
The company is scheduled to report earnings on October 30. Zacks consensus estimates project earnings of $2.17 per share, down 8.82% from the same quarter last year, and revenue of $16.07 billion, up 5.82%.
The consensus estimate for earnings per share has fallen 8.05% over the past 30 days, according to Zacks. For the full year, Zacks forecasts earnings of $9.37 per share and revenue of $63.12 billion, respective increases of 2.29% and 7.45% from the prior year.
Before the latest session, AstraZeneca shares had gained 2.48% over the past month. The Medical sector and S&P 500 were down 0.67% and 0.24%, respectively, over that period.
This article was produced with the help of AI technology.
Source: Yahoo Finance
